Toxic epidermal necrolysis (Lyell's disease)

Burns

Volumn 36, Issue 2, 2010, Pages 152-163

  Lissia, Mario ^a   Mulas, Pietro ^a   Bulla, Antonio ^a   Rubino, Corrado ^a  

^a UNIVERSITY OF SASSARI   (Italy)

Author keywords

Drug reactions; IVIG; Lyell's disease; Plasmapheresis; SCORTEN; Stevens Johnson's syndrome

Indexed keywords

BIOBRANE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; IMMUNOGLOBULIN; INFLIXIMAB; METHYLPREDNISOLONE; SULFADIAZINE SILVER; SULFONAMIDE; THALIDOMIDE; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ANTIBIOTIC THERAPY; BURN; CLINICAL TRIAL; CROHN DISEASE; DRUG HYPERSENSITIVITY; GRAFT REJECTION; GRAFT VERSUS HOST REACTION; HUMAN; IMMUNOPATHOLOGY; PLASMAPHERESIS; REVIEW; RHEUMATOID ARTHRITIS; SKIN INJURY; STEVENS JOHNSON SYNDROME; TOTAL PARENTERAL NUTRITION; TOXIC EPIDERMAL NECROLYSIS; WOUND CARE; WOUND DRESSING; WOUND INFECTION;

EPIDERMAL NECROLYSIS, TOXIC; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOSUPPRESSIVE AGENTS; PLASMAPHERESIS; SKIN;

EID: 76349090218     PISSN: 03054179     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.burns.2009.06.213     Document Type: Review

References (135)

1. Stevens A.M., and Johnson F.C. A new eruptive fever associated with stomatitis and ophthalmia: report of two cases in children. Am J Dis Child 24 (1922) 526-533
2. Lyell A. Toxic epidermal necrolysis: an eruption resembling scalding of the skin. Br J Dermatol 68 (1956) 355-361
3. In: Freedberg I.M. (Ed). Fitzpatrick's dermatology in general medicine (2003), McGraw-Hill
4. Thomas C.C., and Hardy M.K. Bullous-skin eruptions following sulfonamide administration: relationship to bullous erythema multiforme. J Am Med Womens Assoc 3 (1948) 1-3
5. Williams P.M., and Conklin R.J. Erythema multiforme: a review and contrast from Stevens-Johnson syndrome/toxic epidermal necrolysis. Dent Clin North Am 49 (2005) 67-76
6. Roujeau J.C. The spectrum of Stevens-Johnson syndrome and toxic epidermal necrolysis: a clinical classification. J Invest Dermatol 102 (1994) 28S-30S
7. Laguna C., Martin B., Torrijos A., Garcia-Melgares M., and Febrer I. Sindrome de Stevens-Johnson y necrolisis epidermica toxica: experiencia clinica y revision de la literatura especializada. Actas Dermosifiliogr 97 (2006) 177-185 [impresa]
8. Khalili B., and Bahna S.L. Pathogenesis and recent therapeutic trends in Stevens-Johnson syndrome and toxic epidermal necrolysis. Ann Allergy Asthma Immunol 97 (2006) 272-281
9. Letko E., Papaliodis D.N., Papaliodis G.N., Daoud Y.J., Ahmed A.R., and Foster C.S. Stevens-Johnson syndrome and toxic epidermal necrolysis: a review of the literature. Ann Allergy Asthma Immunol 94 (2005) 419-436
10. Lamoreux M.R., Sternbach M.R., and Hsu W.T. Erythema multiforme. Am Fam Physician 74 (2006) 1883-1888
11. Assier H., Bastuji-Garin S., Revuz J., and Roujeau J.C. Erythema multiforme with mucous membrane involvement and Stevens-Johnson syndrome are clinically different disorders with distinct causes. Arch Dermatol 131 (1995) 539-543
12. Chan H.L., Stern R.S., Arndt K.A., Langlois J., Jick S.S., Jick H., et al. The incidence of erythema multiforme, Stevens-Johnson syndrome, and toxic epidermal necrolysis. A population-based study with particular reference to reactions caused by drugs among outpatients. Arch Dermatol 126 (1990) 43-47
13. Chave T.A., Mortimer N.J., Sladden M.J., Hall A.P., and Hutchinson P.E. Toxic epidermal necrolysis: current evidence, practical management and future directions. Br J Dermatol 153 (2005) 241-253
14. Trent J., Halem M., French L.E., and Kerdel F. Toxic epidermal necrolysis and intravenous immunoglobulin: a review. Semin Cutan Med Surg 25 (2006) 91-93
15. Roujeau J.C., Guillaume J.C., Fabre J.P., Penso D., Flechet M.L., and Girre J.P. Toxic epidermal necrolysis (Lyell syndrome). Incidence and drug etiology in France, 1981-1985. Arch Dermatol 126 (1990) 37-42
16. Strom B.L., Carson J.L., Halpern A.C., Schinnar R., Snyder E.S., Shaw M., et al. A population-based study of Stevens-Johnson syndrome. Incidence and antecedent drug exposures. Arch Dermatol 127 (1991) 831-838
17. Rzany B., Hering O., Mockenhaupt M., Schröder W., Goerttler E., Ring J., et al. Histopathological and epidemiological characteristics of patients with erythema exudativum multiforme major, Stevens-Johnson syndrome and toxic epidermal necrolysis. Br J Dermatol 135 (1996) 6-11
18. French L.E., Trent J.T., and Kerdel F.A. Use of intravenous immunoglobulin in toxic epidermal necrolysis and Stevens-Johnson syndrome: our current understanding. Int Immunopharmacol 6 (2006) 543-549
19. Roujeau J.C., Kelly J.P., Naldi L., Rzany B., Stern R.S., Anderson T., et al. Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. N Engl J Med 333 (1995) 1600-1607
20. Ducic I., Shalom A., Rising W., Nagamoto K., and Munster A.M. Outcome of patients with toxic epidermal necrolysis syndrome revisited. Plast Reconstr Surg 110 (2002) 768-773
21. Bastuji-Garin S., Fouchard N., Bertocchi M., Roujeau J.C., Revuz J., Wolkenstein P., et al. SCORTEN: a severity-of-illness score for toxic epidermal necrolysis. J Invest Dermatol 115 (2000) 149-153
22. Schwartz R. Toxic epidermal necrolysis. Cutis 59 (1997) 123-128 [New York, NY]
23. Leone R., Venegoni M., Motola D., Moretti U., Piazzetta V., Cocci A., et al. Adverse drug reactions related to the use of fluoroquinolone antimicrobials: an analysis of spontaneous reports and fluoroquinolone consumption data from three Italian regions. Drug Safe 26 (2003) 109-120
24. In: Litt J.Z. (Ed). Litt's drug eruption reference manual (2005), Taylor & Francis
25. Pereira F.A., Mudgil A.V., and Rosmarin D.M. Toxic epidermal necrolysis. J Am Acad Dermatol 56 (2007) 181-200
26. Borchers A.T., Lee J.L., Naguwa S.M., Cheema G.S., and Gershwin M.E. Stevens-Johnson syndrome and toxic epidermal necrolysis. Autoimmun Rev 7 (2008) 598-605
27. Mockenhaupt M., Viboud C., Dunant A., Naldi L., Halevy S., Bavinck J.N.B., et al. Stevens-Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR-Study. J Invest Dermatol 128 (2007) 35-44
28. Takeda H., Mitsuhashi Y., Kondo S., Kato Y., and Tajima K. Toxic epidermal necrolysis possibly linked to hyperacute graft-versus-host disease after allogeneic bone marrow transplantation. J Dermatol 24 (1997) 635-641
29. Stone N., Sheerin S., and Burge S. Toxic epidermal necrolysis and graft vs. host disease: a clinical spectrum but a diagnostic dilemma. Clin Exp Dermatol (Print) 24 (1999) 260-262
30. Radimer G.F., Davis J.H., and Ackerman A.B. Fumigant-induced toxic epidermal necrolysis. Arch Dermatol 110 (1974) 103-104
31. House R., Jakubovic H., Wong L., and Holness D. Work-related toxic epidermal necrolysis?. J Occup Med 34 (1992) 135-139
32. Martine J., and Bindert T. Une complication rare de la vaccination jennerienne. Le necrolyse epidermique. Schweiz Med Wochenschr 101 (1971) 1446-1450
33. Shoss R.G., and Rayhanzadeh S. Toxic epidermal necrolysis following measles vaccination. Arch Dermatol 110 (1974) 766-770
34. Avakian R., Flowers F., Araujo O., and Ramos-Caro F. Toxic epidermal necrolysis: a review. J Am Acad Dermatol 25 (1991) 69-79
35. Beare M. Toxic epidermal necrolysis. Arch Dermatol 86 (1962) 638-653
36. Dobrosavljevic D., Milinkovic M.V., and Nikolic M.M. Toxic epidermal necrolysis following morbilli-parotitis-rubella vaccination. J Eur Acad Dermatol Venereol 13 (1999) 59-61
37. Stevens D., Swift P.G., Johnston P.G., Kearney P.J., Corner B.D., and Burman D. Mycoplasma pneumoniae infections in children. Arch Dis Child 53 (1978) 38-42
38. Fournier S., Bastuji-Garin S., Mentec H., Revuz J., and Roujeau J. Toxic epidermal necrolysis associated with Mycoplasma pneumoniae infection. Eur J Clin Microbiol Infect Dis (Print) 14 (1995) 558-559
39. Lam N., Yang Y., Wang L., Lin Y., and Chiang B. Clinical characteristics of childhood erythema multiforme, Stevens-Johnson syndrome and toxic epidermal necrolysis in Taiwanese children. J Microbiol Immunol Infect 37 (2004) 366-370
40. Hung S.I., Chung W.H., Liou L.B., Chu C.C., Lin M., Huang H.P., et al. HLA-B* 5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. Proc Natl Acad Sci 102 (2005) 4134-4139
41. Hung S.I., Chung W.H., Jee S.H., Chen W.C., Chang Y.T., Lee W.R., et al. Genetic susceptibility to carbamazepine-induced cutaneous adverse drug reactions. Pharmacogenet Genom 16 (2006) 297-306
42. Paquet P., Paquet F., Al Saleh W., Reper P., Vanderkelen A., and Piérard G.E. Immunoregulatory effector cells in drug-induced toxic epidermal necrolysis. Am J Dermatopathol 22 (2000) 413-417
43. Correia O., Delgado L., Ramos J.P., Resende C., and Torrinha J.A. Cutaneous T-cell recruitment in toxic epidermal necrolysis. Further evidence of CD8+ lymphocyte involvement. Arch Dermatol 129 (1993) 466-468
44. Nassif A., Bensussan A., Dorothée G., Mami-Chouaib F., Bachot N., Bagot M., et al. Drug specific cytotoxic T-cells in the skin lesions of a patient with toxic epidermal necrolysis. J Invest Dermatol 118 (2002) 728-733
45. Nassif A., Bensussan A., Boumsell L., Deniaud A., Moslehi H., Wolkenstein P., et al. Toxic epidermal necrolysis: effector cells are drug-specific cytotoxic T cells. J Allergy Clin Immunol 114 (2004) 1209-1215
46. Friedmann P.S., Strickland I., Pirmohamed M., and Park B.K. Investigation of mechanisms in toxic epidermal necrolysis induced by carbamazepine. Arch Dermatol 130 (1994) 598-604
47. Paquet P., Jacob E., Damas P., Pirson J., and Piérard G. Analytical quantification of the inflammatory cell infiltrate and CD95R expression during treatment of drug-induced toxic epidermal necrolysis. Arch Dermatol Res 297 (2005) 266-273
48. Blanca M., Posadas S., Torres M.J., Leyva L., Mayorga C., Gonzalez L., et al. Expression of the skin-homing receptor in peripheral blood lymphocytes from subjects with nonimmediate cutaneous allergic drug reactions. Allergy 55 (2000) 998-1004
49. Kano Y., Hirahara K., Mitsuyama Y., Takahashi R., and Shiohara T. Utility of the lymphocyte transformation test in the diagnosis of drug sensitivity: dependence on its timing and the type of drug eruption. Allergy 62 (2007) 1439-1444
50. Paquet P., Nikkels A., Arrese J.E., Vanderkelen A., and Piérard G.E. Macrophages and tumor necrosis factor alpha in toxic epidermal necrolysis. Arch Dermatol 130 (1994) 605-608
51. Le Cleach L., Delaire S., Boumsell L., Bagot M., Bourgault-Villada I., Bensussan A., et al. Blister fluid T lymphocytes during toxic epidermal necrolysis are functional cytotoxic cells which express human natural killer (NK) inhibitory receptors. Clin Exp Immunol 119 (2000) 225-230
52. Caproni M., Torchia D., Schincaglia E., Volpi W., Frezzolini A., Schena D., et al. The CD40/CD40 ligand system is expressed in the cutaneous lesions of erythema multiforme and Stevens-Johnson syndrome/toxic epidermal necrolysis spectrum. Br J Dermatol 154 (2006) 319-324
53. Dietrich A., Kawakubo Y., Rzany B., Mockenhaupt M., Simon J.C., and Schöpf E. Low N-acetylating capacity in patients with Stevens-Johnson syndrome and toxic epidermal necrolysis. Exp Dermatol 4 (1995) 313-316
54. Roujeau J. Immune mechanisms in drug allergy. Allergol Int 55 (2006) 27-33
55. Chung W., Hung S., Hong H., Hsih M., Yang L., Ho H., et al. Medical genetics: a marker for Stevens-Johnson syndrome. Nature 428 (2004) 486
56. Chung W., Hung S., and Chen Y. Human leukocyte antigens and drug hypersensitivity. Curr Opin Allergy Clin Immunol 7 (2007) 317-323
57. Kindt T.J., Goldsby R.A., and Osborne B.A. Kuby immunology (2006), WH Freeman
58. Paul C., Wolkenstein P., Adle H., Wechsler J., Garchon H.J., Revuz J., et al. Apoptosis as a mechanism of keratinocyte death in toxic epidermal necrolysis. Br J Dermatol 134 (1996) 710-714
59. Viard I., Wehrli P., Bullani R., Schneider P., Holler N., Salomon D., et al. Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin. Science 282 (1998) 490-493
60. Knox P.G., Milner A.E., Green N.K., Eliopoulos A.G., and Young L.S. Inhibition of metalloproteinase cleavage enhances the cytotoxicity of Fas ligand. J Immunol 170 (2003) 677-685
61. Nassif A., Moslehi H., Le Gouvello S., Bagot M., Lyonnet L., Michel L., et al. Evaluation of the potential role of cytokines in toxic epidermal necrolysis. J Invest Dermatol 123 (2004) 850-855
62. Abe R., Shimizu T., Shibaki A., Nakamura H., Watanabe H., and Shimizu H. Toxic epidermal necrolysis and Stevens-Johnson syndrome are induced by soluble Fas ligand. Am J Pathol 162 (2003) 1515-1520
63. Posadas S.J., Padial A., Torres M.J., Mayorga C., Leyva L., Sanchez E., et al. Delayed reactions to drugs show levels of perforin, granzyme B, and Fas-L to be related to disease severity. J Allergy Clin Immunol 109 (2002) 155-161
64. Posadas S.J., Torres M.J., Mayorga C., Juarez C., and Blanca M. Gene expression levels of cytokine profile and cytotoxic markers in non-immediate reactions to drugs. Blood Cells Mol Dis 29 (2002) 179-189
65. Caproni M., Torchia D., Schincaglia E., Volpi W., Frezzolini A., Schena D., et al. Expression of cytokines and chemokine receptors in the cutaneous lesions of erythema multiforme and Stevens-Johnson syndrome/toxic epidermal necrolysis. Br J Dermatol 155 (2006) 722-728
66. Arnold R., Seifert M., Asadullah K., and Volk H.D. Crosstalk between keratinocytes and T lymphocytes via Fas/Fas ligand interaction: modulation by cytokines. J Immunol 162 (1999) 7140-7147
67. Correia O., Delgado L., Barbosa I.L., Campilho F., and Fleming-Torrinha J. Increased interleukin 10, tumor necrosis factor alpha, and interleukin 6 levels in blister fluid of toxic epidermal necrolysis. J Am Acad Dermatol 47 (2002) 58-62
68. Lebargy F., Wolkenstein P., Gisselbrecht M., Lange F., Fleury-Feith J., Delclaux C., et al. Pulmonary complications in toxic epidermal necrolysis: a prospective clinical study. Intensive Care Med 23 (1997) 1237-1244
69. Revuz J., Penso D., Roujeau J.C., Guillaume J.C., Payne C.R., Wechsler J., et al. Toxic epidermal necrolysis. Clinical findings and prognosis factors in 87 patients. Arch Dermatol 123 (1987) 1160-1165
70. Sugimoto Y., Mizutani H., Sato T., Kawaura N., Ohkouchi K., and Shimizu M. Toxic epidermal necrolysis with severe gastrointestinal mucosal cell death: a patient who excreted long tubes of dead intestinal epithelium. J Dermatol 25 (1998) 533-538
71. Wong K.C., Kennedy P.J., and Lee S. Clinical manifestations and outcomes in 17 cases of Stevens-Johnson syndrome and toxic epidermal necrolysis. Australas J Dermatol 40 (1999) 131-134
72. Atiyeh B.S., Dham R., Yassin M.F., and El-Musa K.A. Treatment of toxic epidermal necrolysis with moisture-retentive ointment: a case report and review of the literature. Dermatol Surg 29 (2003) 185-188
73. Mofid M.Z., Costarangos C., Bernstein B., Wong L., Munster A., and Nousari H.C. Drug-induced linear immunoglobulin A bullous disease that clinically mimics toxic epidermal necrolysis. J Burn Care Rehabil 21 (2000) 246-247
74. Magina S., Lisboa C., Leal V., Palmares J., and Mesquita-Guimarães J. Dermatological and ophthalmological sequels in toxic epidermal necrolysis. Dermatology (Basel) 207 (2003) 33-36
75. Roujeau J.C., Phlippoteau C., Koso M., Wechsler J., Andre C., Binaghi M., et al. Sjögren-like syndrome after drug-induced toxic epidermal necrolysis. Lancet 1 (1985) 609-611
76. Di Pascuale M.A., Espana E.M., Liu D.T., Kawakita T., Li W., Gao Y.Y., et al. Correlation of corneal complications with eyelid cicatricial pathologies in patients with Stevens-Johnson syndrome and toxic epidermal necrolysis syndrome. Ophthalmology 112 (2005) 904-912
77. Haber J., Hopman W., Gomez M., and Cartotto R. Late outcomes in adult survivors of toxic epidermal necrolysis after treatment in a burn center. J Burn Care Rehabil 26 (2005) 33-41
78. Gueudry J., Roujeau J., Binaghi M., Soubrane G., and Muraine M. Risk factors for the development of ocular complications of Stevens-Johnson syndrome and toxic epidermal necrolysis. Arch Dermatol 145 (2009) 157-162
79. Sedghizadeh P.P., Kumar S.K.S., Gorur A., Mastin C., and Boros A.L. Toxic epidermal necrolysis with a rare long-term oral complication requiring surgical intervention. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 105 (2008) e29-e33
80. Kelemen III J.J., Cioffi W.G., McManus W.F., Mason A.D.J., and Pruitt B.A.J. Burn center care for patients with toxic epidermal necrolysis. J Am Coll Surg 180 (1995) 273-278
81. Khoo A.K., and Foo C.L. Toxic epidermal necrolysis in a burns centre: a 6-year review. Burns 22 (1996) 275-278
82. Yarbrough D.R. Experience with toxic epidermal necrolysis treated in a burn center. J Burn Care Rehabil 17 (1996) 30-33
83. McGee T., and Munster A. Toxic epidermal necrolysis syndrome: mortality rate reduced with early referral to regional burn center. Plast Reconstr Surg 102 (1998) 1018-1022
84. Palmieri T.L., Greenhalgh D.G., Saffle J.R., Spence R.J., Peck M.D., Jeng J.C., et al. A multicenter review of toxic epidermal necrolysis treated in U.S. burn centers at the end of the twentieth century. J Burn Care Rehabil 23 (2002) 87-96
85. Fromowitz J., Ramos-Caro F., Flowers F., and University of Florida. Practical guidelines for the management of toxic epidermal necrolysis and Stevens-Johnson syndrome. Int J Dermatol 46 (2007) 1092-1094
86. Gravante G., Esposito G., Piazzolla M., Marianetti M., Delogu D., and Montone A. Nutrition of toxic epidermal necrolysis. J Hum Nutr Diet 19 (2006) 152-153 [author reply 153-5; 2006]
87. Coss-Bu J.A., Jefferson L.S., Levy M.L., Walding D., David Y., and Klish W.J. Nutrition requirements in patients with toxic epidermal necrolysis. Nutr Clin Pract 12 (1997) 81-84
88. Windle E.M. Immune modulating nutrition support for a patient with severe toxic epidermal necrolysis. J Hum Nutr Diet 18 (2005) 311-314
89. Schulz J.T., Sheridan R.L., Ryan C.M., MacKool B., and Tompkins R.G. A 10-year experience with toxic epidermal necrolysis. J Burn Care Rehabil 21 (2000) 199-204
90. Garcia-Doval I., LeCleach L., Bocquet H., Otero X.L., and Roujeau J.C. Toxic epidermal necrolysis and Stevens-Johnson syndrome: does early withdrawal of causative drugs decrease the risk of death?. Arch Dermatol 136 (2000) 323-327
91. Ying S., Ho W., and Chan H.H. Toxic epidermal necrolysis: 10 years experience of a burns centre in Hong Kong. Burns 27 (2001) 372-375
92. Bamichas G., Natse T., Christidou F., Stangou M., Karagianni A., Koukourikos S., et al. Plasma exchange in patients with toxic epidermal necrolysis. Ther Apher Dial 6 (2002) 225-228
93. Ellis M.W., Oster C.N., Turiansky G.W., and Blanchard J.R. A case report and a proposed algorithm for the transfer of patients with Stevens-Johnson syndrome and toxic epidermal necrolysis to a burn center. Mil Med 167 (2002) 701-704
94. ® dressing in a young infant with TEN. Pediatr Dermatol 25 (2008) 541-543
95. Parsons J.M. Toxic epidermal necrolysis. Int J Dermatol 31 (1992) 749-768
96. Manders S.M. Serious and life-threatening drug eruptions. Am Fam Physician 51 (1995) 1865-1872
97. Atiyeh B.S., Dham R., Kadry M., Abdallah A.F., Al-Oteify M., Fathi O., et al. Benefit-cost analysis of moist exposed burn ointment. Burns 28 (2002) 659-663
98. Kucan J.O. Use of Biobrane in the treatment of toxic epidermal necrolysis. J Burn Care Rehabil 16 (1995) 324-327 [discussion 327-8; 1995]
99. ® for skin coverage reduces pain, improves mobilisation and decreases infection in elderly patients. Burns 34 (2008) 487-492
100. Wolkenstein P., and Revuz J. Toxic epidermal necrolysis. Dermatol Clin 18 (2000) 485-495 [ix]
101. Pianigiani E., Ierardi F., Taddeucci P., Perotti R., Biagioli M., Di Simplicio F.C., et al. Skin allograft in the treatment of toxic epidermal necrolysis (TEN). Dermatol Surg 28 (2002) 1173-1176
102. ®. J Eur Acad Dermatol Venereol 21 (2007) 426-427
103. ® Ag in the treatment of toxic epidermal necrolysis (TEN). Burns 34 (2008) 63-66
104. Schneck J., Fagot J., Sekula P., Sassolas B., Roujeau J.C., and Mockenhaupt M. Effects of treatments on the mortality of Stevens-Johnson syndrome and toxic epidermal necrolysis: a retrospective study on patients included in the prospective EuroSCAR Study. J Am Acad Dermatol 58 (2008) 33-40
105. Halebian P.H., Corder V.J., Madden M.R., Finklestein J.L., and Shires G.T. Improved burn center survival of patients with toxic epidermal necrolysis managed without corticosteroids. Ann Surg 204 (1986) 503-512
106. Tegelberg-Stassen M.J., van Vloten W.A., and Baart de la Faille H. Management of nonstaphylococcal toxic epidermal necrolysis: follow-up study of 16 case histories. Dermatologica 180 (1990) 124-129
107. Rzany B., Schmitt H., and Schöpf E. Toxic epidermal necrolysis in patients receiving glucocorticosteroids. Acta Derm Venereol 71 (1991) 171-172
108. Criton S., Devi K., Sridevi P.K., and Asokan P.U. Toxic epidermal necrolysis-a retrospective study. Int J Dermatol 36 (1997) 923-925
109. Engelhardt S.L., Schurr M.J., and Helgerson R.B. Toxic epidermal necrolysis: an analysis of referral patterns and steroid usage. J Burn Care Rehabil 18 (1997) 520-524
110. Kardaun S.H., and Jonkman M.F. Dexamethasone pulse therapy for Stevens-Johnson syndrome/toxic epidermal necrolysis. Acta Derm Venereol 87 (2007) 144-148
111. Guibal F., Bastuji-Garin S., Chosidow O., Saiag P., Revuz J., and Roujeau J.C. Characteristics of toxic epidermal necrolysis in patients undergoing long-term glucocorticoid therapy. Arch Dermatol 131 (1995) 669-672
112. Samimi S.S., and Siegfried E. Stevens-Johnson syndrome developing in a girl with systemic lupus erythematosus on high-dose corticosteroid therapy. Pediatr Dermatol 19 (2002) 52-55
113. Frangogiannis N.G., Boridy I., Mazhar M., Mathews R., Gangopadhyay S., and Cate T. Cyclophosphamide in the treatment of toxic epidermal necrolysis. South Med J 89 (1996) 1001-1003
114. Trautmann A., Klein C.E., Kämpgen E., and Bröcker E.B. Severe bullous drug reactions treated successfully with cyclophosphamide. Br J Dermatol 139 (1998) 1127-1128
115. Arévalo J.M., Lorente J.A., González-Herrada C., and Jiménez-Reyes J. Treatment of toxic epidermal necrolysis with cyclosporin A. J Trauma 48 (2000) 473-478
116. Jarrett P., Rademaker M., Havill J., and Pullon H. Toxic epidermal necrolysis treated with cyclosporin and granulocyte colony stimulating factor. Clin Exp Dermatol 22 (1997) 146-147
117. Wolkenstein P., Latarjet J., Roujeau J.C., Duguet C., Boudeau S., Vaillant L., et al. Randomised comparison of thalidomide versus placebo in toxic epidermal necrolysis. Lancet 352 (1998) 1586-1589
118. Fischer M., Fiedler E., Marsch W.C., and Wohlrab J. Antitumour necrosis factor-alpha antibodies (Infliximab) in the treatment of a patient with toxic epidermal necrolysis. Br J Dermatol 146 (2002) 707-709
119. Chaidemenos G.C., Chrysomallis F., Sombolos K., Mourellou O., Ioannides D., and Papakonstantinou M. Plasmapheresis in toxic epidermal necrolysis. Int J Dermatol 36 (1997) 218-221
120. Kamanabroo D., Schmitz-Landgraf W., and Czarnetzki B.M. Plasmapheresis in severe drug-induced toxic epidermal necrolysis. Arch Dermatol 121 (1985) 1548-1549
121. Egan C.A., Grant W.J., Morris S.E., Saffle J.R., and Zone J.J. Plasmapheresis as an adjunct treatment in toxic epidermal necrolysis. J Am Acad Dermatol 40 (1999) 458-461
122. Roujeau J.C., Chosidow O., Saiag P., and Guillaume J.C. Toxic epidermal necrolysis (Lyell syndrome). J Am Acad Dermatol 23 (1990) 1039-1058
123. Sakellariou G., Koukoudis P., Karpouzas J., Alexopoulos E., Papadopoulou D., Chrisomalis F., et al. Plasma exchange (PE) treatment in drug-induced toxic epidermal necrolysis (TEN). Int J Artif Organs 14 (1991) 634-638
124. Kazatchkine M.D., and Kaveri S.V. Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. N Engl J Med 345 (2001) 747-755
125. Prins C., Kerdel F.A., Padilla R.S., Hunziker T., Chimenti S., Viard I., et al. Treatment of toxic epidermal necrolysis with high-dose intravenous immunoglobulins: multicenter retrospective analysis of 48 consecutive cases. Arch Dermatol 139 (2003) 26-32
126. Brown K.M., Silver G.M., Halerz M., Walaszek P., Sandroni A., and Gamelli R.L. Toxic epidermal necrolysis: does immunoglobulin make a difference?. J Burn Care Rehabil 25 (2004) 81-88
127. Stella M., Clemente A., Bollero D., Risso D., and Dalmasso P. Toxic epidermal necrolysis (TEN) and Stevens-Johnson syndrome (SJS): experience with high-dose intravenous immunoglobulins and topical conservative approach. A retrospective analysis. Burns 33 (2007) 452-459
128. Paquet P., Jacob E., Damas P., and Piérard G.E. Treatment of drug-induced toxic epidermal necrolysis (Lyell's syndrome) with intravenous human immunoglobulins. Burns 27 (2001) 652-655
129. Trent J.T., Kirsner R.S., Romanelli P., and Kerdel F.A. Analysis of intravenous immunoglobulin for the treatment of toxic epidermal necrolysis using SCORTEN: the University of Miami experience. Arch Dermatol 139 (2003) 39-43
130. Shortt R., Gomez M., Mittman N., and Cartotto R. Intravenous immunoglobulin does not improve outcome in toxic epidermal necrolysis. J Burn Care Rehabil 25 (2004) 246-255
131. Bachot N., Revuz J., and Roujeau J. Intravenous immunoglobulin treatment for Stevens-Johnson syndrome and toxic epidermal necrolysis: a prospective noncomparative study showing no benefit on mortality or progression. Arch Dermatol 139 (2003) 33-36
132. Lissia M., Figus A., and Rubino C. Intravenous immunoglobulins and plasmapheresis combined treatment in patients with severe toxic epidermal necrolysis: preliminary report. Br J Plast Surg 58 (2005) 504-510
133. Yamada H., and Takamori K. Status of plasmapheresis for the treatment of toxic epidermal necrolysis in Japan. Ther Apher Dial 12 (2008) 355-359
134. Michael D., and Grando S.A. Novel mechanism for therapeutic action of IVIg in autoimmune blistering dermatoses. Curr Dir Autoimmun 10 (2008) 333-343
135. Kreis B.E., Middelkoop E., Vloemans A.F.P.M., and Kreis R.W. The use of a PEG tube in a burn centre. Burns 28 (2002) 191-197